Syndax Pharmaceuticals
SNDX
139 hedge funds and large institutions have $1.39B invested in Syndax Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 61 increasing their positions, 27 reducing their positions, and 12 closing their positions.
1,129% more call options, than puts
Call options by funds: $5.43M | Put options by funds: $442K
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
126% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 27
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
37% more capital invested
Capital invested by funds: $1.02B → $1.39B (+$373M)
15% more funds holding
Funds holding: 121 → 139 (+18)
7.66% more ownership
Funds ownership: 98.21% → 105.87% (+7.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$37M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$26.5M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$17.7M |
| 4 |
CC
Commodore Capital
New York
|
+$16.6M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$28.9M |
| 2 |
DM
Deerfield Management
New York
|
-$21.4M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$12.5M |
| 4 |
6CM
683 Capital Management
New York
|
-$10.1M |
| 5 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$10.1M |
SNDX Hedge Fund Activity: Q3 2022 in Review
139 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2022, worth a combined $1.39B — up 37% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SNDX positions and 12 closed out — a net gain of 18 holders — while 61 added to existing stakes and 27 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $37M. The largest seller was Nantahala Capital Management, cutting an estimated $28.9M.
- 139 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2022, up from 121 in Q2 2022.
- Funds reported $1.39B of Syndax Pharmaceuticals stock for Q3 2022, up 37% quarter-over-quarter.
- 30 funds opened new Syndax Pharmaceuticals positions in Q3 2022 and 12 closed out, a net change of +18 holders.
- The largest Syndax Pharmaceuticals buyer in Q3 2022 was Jennison Associates, an estimated $37M added.
- The largest Syndax Pharmaceuticals seller in Q3 2022 was Nantahala Capital Management, an estimated $28.9M sold.
Based on aggregated 13F filings for Q3 2022.